Articles

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
ImmunoGen, Inc., Waltham, MA
ImmunoGen, Inc., Waltham, MA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
ImmunoGen, Inc., Waltham, MA
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Vol. 104 No. 4 (2019): April, 2019 https://doi.org/10.3324/haematol.2018.205252